Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral TherapyHwai‐I Yang, Mindie H. Nguyen, Dong-Hyun Lee et al.|The Journal of Infectious Diseases|2019Cited by 101
Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavirChien‐Hung Chen, Cheng‐Yuan Peng, Chuan-Mo Lee et al.|Oncotarget|2017Cited by 61
New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitisHung‐Wei Wang, Guan‐Tarn Huang, Cheng‐Yuan Peng et al.|Scientific Reports|2017Cited by 57
Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis BCheng‐Yuan Peng, Ching-Hsiang Chen, Hsueh‐Chou Lai et al.|Scientific Reports|2017Cited by 23
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular CarcinomaHung‐Wei Wang, Cheng‐Yuan Peng, Tsung‐Hui Hu et al.|Cancers|2020Cited by 14